Get the Stockscreener App
83.24
0.67%
0.55
Edwards Lifesciences Corp stock is traded at $83.24, with a volume of 2.00M.
It is up +0.67% in the last 24 hours and up +7.03% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$82.69
Open:
$82.95
24h Volume:
2.00M
Relative Volume:
0.47
Market Cap:
$48.87B
Revenue:
$5.69B
Net Income/Loss:
$1.41B
P/E Ratio:
11.92
EPS:
6.9828
Net Cash Flow:
$577.90M
1W Performance:
+8.77%
1M Performance:
+7.03%
6M Performance:
+10.27%
1Y Performance:
+21.29%
1-Day Range:
$82.35
$83.71
1-Week Range:
$75.48
$84.66
52-Week Range:
$64.89
$84.66
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
83.25 | 48.55B | 5.69B | 1.41B | 577.90M | 6.9828 |
|
ABT
Abbott Laboratories
|
124.93 | 216.57B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
101.42 | 148.62B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
370.52 | 141.30B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
91.48 | 117.65B | 34.20B | 4.69B | 5.30B | 3.6218 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Econ Financial Services Corp Makes New $889,000 Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Jennison Associates LLC Raises Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
What is the fair value of Edwards Lifesciences Corporation stock nowWeekly Market Summary & Real-Time Price Movement Reports - newser.com
Quantitative breakdown of Edwards Lifesciences Corporation recent moveQuarterly Portfolio Report & Weekly Setup with ROI Potential - newser.com
How Edwards Lifesciences Corporation (EWL) stock responds to bond marketJuly 2025 Intraday Action & Free AI Powered Buy and Sell Recommendations - newser.com
Why Edwards Lifesciences (EW) Is Up 7.6% After Positive Long-Term Data for SAPIEN Valve Platform - Yahoo Finance
Why Analysts Say Edwards Lifesciences Story Is Evolving With New Data and Market Shifts - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Market Activity and S&P 500 Futures - Kalkine Media
Edwards Lifesciences Corp. Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Wolfe Research Upgrades Edwards Lifesciences (EW) Rating to 'Pee - GuruFocus
Edwards Lifesciences (EW) Receives Upgrade to 'Buy' from Jefferies | EW Stock News - GuruFocus
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Is Edwards Lifesciences Corporation (EWL) stock resilient in recession scenarios2025 Top Gainers & Trade Opportunity Analysis - newser.com
Teacher Retirement System of Texas Boosts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Using data models to predict Edwards Lifesciences Corporation stock movement2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com
Why Edwards Lifesciences Corporation stock is a must watch in 20252025 Volatility Report & AI Enhanced Market Trend Forecasts - Fundação Cultural do Pará
Truist Securities Raises Price Target for Edwards Lifesciences (EW) | EW Stock News - GuruFocus
Data from Partner 3 low-risk affirms TAVR even with SAVR - BioWorld MedTech
Edwards Lifesciences stock price target raised to $87 by Truist on positive trial data - Investing.com
Truist Raises Price Target on Edwards Lifesciences to $87 From $82, Keeps Hold Rating - MarketScreener
Edwards Lifesciences Corporation stock trend forecastWeekly Market Summary & Expert Approved Momentum Ideas - newser.com
Will Edwards Lifesciences Corporation stock return to pre crash levels2025 Dividend Review & Fast Entry Momentum Alerts - newser.com
How robust is Edwards Lifesciences Corporation (EWL) stock financial positionWeekly Profit Summary & Free Weekly Watchlist of Top Performers - newser.com
Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 - BioSpace
What dividend safety score for Edwards Lifesciences Corporation stock2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Using Python tools to backtest Edwards Lifesciences Corporation strategiesMarket Performance Summary & AI Forecasted Entry and Exit Points - newser.com
EW Investor News: Rosen Law Firm Investigates Breaches of - GlobeNewswire
PATENT—Fed. Cir.: Noninfringement ruling for Edwards Lifesciences in heart valve patent suit affirmed on appeal - VitalLaw.com
Edwards Lifesciences’ INNOVALVE System: A Promising Step in Mitral Valve Treatment - TipRanks
Is Edwards Lifesciences Corporation stock cheap by valuation metricsWeekly Investment Report & Weekly Watchlist of Top Performers - newser.com
Edwards Lifesciences’ PROGRESS Trial: A Game-Changer in Aortic Stenosis Treatment? - TipRanks
Edwards Lifesciences’ New Study on Continuous Blood Pressure Monitoring: What Investors Should Know - TipRanks
Edwards Lifesciences’ ALT-FLOW II Trial: A New Hope for Heart Failure Treatment? - TipRanks
Edwards Lifesciences’ PASCAL System: A Pivotal Study Update - TipRanks
Edwards Lifesciences reports positive outcomes for heart valve therapies - Investing.com
Edwards Lifesciences Advances Monitoring Tech with New Study - TipRanks
Edwards Lifesciences’ ENCIRCLE Trial: A New Hope for Mitral Regurgitation Patients - TipRanks
Edwards Lifesciences’ MITRIS Valve Study: A Potential Game-Changer in Mitral Valve Replacement - TipRanks
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences (EW) Sees Positive Movement After Trial Dat - GuruFocus
Edwards Lifesciences’ Real-World Study on INSPIRIS RESILIA Aortic Valve: A Market Game Changer? - TipRanks
Data backs Edwards Evoque, Sapien M3 tricuspid, mitral valves - MassDevice
Edwards Lifesciences Stock Climbs Amid Clinical Trials - TipRanks
Edwards shares superior long-term outcomes from TAVR studies - MassDevice
Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025 - Yahoo Finance
Edwards Lifesciences’ SAPIEN X4 Study: A Potential Game-Changer in Heart Valve Treatment - TipRanks
Edwards Lifesciences Explores Personalized Blood Pressure Targets in New Study - TipRanks
Edwards Lifesciences’ ALTERRA Study: A Potential Game-Changer in Heart Valve Treatment - TipRanks
Edwards Lifesciences’ MiCLASP Study: A Key Update for Investors - TipRanks
Edwards TAVR shows equivalent outcomes to surgery at seven years - Investing.com
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):